Shares of Hyperion DeFi, Inc. (NASDAQ:HYPD – Get Free Report) have been assigned an average rating of “Hold” from the five brokerages that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $4.5833.
Several equities research analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Hyperion DeFi from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd. Zacks Research upgraded Hyperion DeFi to a “hold” rating in a research note on Monday, December 29th. Chardan Capital set a $7.75 price objective on Hyperion DeFi and gave the company a “buy” rating in a research report on Wednesday, December 24th. Cantor Fitzgerald assumed coverage on Hyperion DeFi in a research note on Tuesday, December 16th. They set an “overweight” rating and a $4.00 target price for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Hyperion DeFi in a research note on Wednesday, October 8th.
View Our Latest Stock Analysis on Hyperion DeFi
Insider Buying and Selling at Hyperion DeFi
Hyperion DeFi Price Performance
NASDAQ:HYPD opened at $3.58 on Wednesday. The stock has a market capitalization of $29.25 million, a PE ratio of -0.89 and a beta of 2.69. Hyperion DeFi has a 1-year low of $0.85 and a 1-year high of $17.18. The firm has a fifty day simple moving average of $4.54 and a 200 day simple moving average of $7.55. The company has a current ratio of 2.25, a quick ratio of 2.25 and a debt-to-equity ratio of 0.11.
Hyperion DeFi (NASDAQ:HYPD – Get Free Report) last announced its quarterly earnings results on Friday, November 14th. The company reported $0.05 EPS for the quarter. The firm had revenue of $0.36 million during the quarter. On average, research analysts expect that Hyperion DeFi will post -41.6 EPS for the current fiscal year.
About Hyperion DeFi
Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.
Featured Stories
- Five stocks we like better than Hyperion DeFi
- Do not delete, read immediately
- If You Keep Cash In A U.S. Bank Account… Read This NOW
- But this $2 Gold Stock Before May 20, 2026
- 3 Overlooked Deductions to Help Potentially Minimize Capital Gains Tax
- Wall Street Stockpicker Names #1 Stock of 2026
Receive News & Ratings for Hyperion DeFi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hyperion DeFi and related companies with MarketBeat.com's FREE daily email newsletter.
